Bicara Therapeutics appoints two directors, Kiran Mazumdar-Shaw leaves board
Bicara Therapeutics appointed Jeremy Bender, Ph.D. and Christy Oliger to its Board of Directors, effective July 28, 2026, increasing the Board from nine to ten members. Director Kiran Mazumdar-Shaw resigned from the Board and its Nominating and Corporate Governance Committee on the same effective date, and the filing says her decision was not the result of any disagreement with the Company. The Board also formed a Launch Readiness Committee to advise management on commercialization strategy for ficerafusp alfa.
Key points
- Jeremy Bender, Ph.D. appointed as a Class I director, serving until the 2028 annual meeting; joins the Audit Committee, replacing Carolyn Ng, Ph.D.
- Christy Oliger appointed as a Class II director, serving until the 2029 annual meeting; joins the Nominating and Corporate Governance Committee.
- Kiran Mazumdar-Shaw resigned from the Board and Nominating and Corporate Governance Committee, effective July 28, 2026.
- Each non-employee director receives an initial option award of 38,950 shares of common stock; the new Launch Readiness Committee is chaired by Kate Haviland.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.